DPP4 and chronic kidney disease: In this study, metformin, either as a monotherapy or in combination with other antidiabetic agents, was the most commonly prescribed treatment for TDM2 among CKD patients, followed by Dipeptidyl peptidase-4 (DPP4) inhibitors, some type of insulins (particularly long-acting and short-acting analogues) and sulfonylureas.